Abstract:Background: Despite the benefits of mesenchymal stromal cell (MSC) transplantation in cardiac tissue, detailed in vivo observations have shown that MSCs only survive for a brief period after transplantation due to harsh microenvironmental conditions, including ischemia, inflammation and anoikis, in the infarcted myocardium. Thus, new strategies are needed to enhance MSC survival and inhibit cardiac remodeling. Studies have now demonstrated that chemokine [C-C motif] ligand 2 (CCL2) and its cognate receptor C-C chemokine receptor 2 (CCR2) promote excessive Ly6C(high) inflammatory monocyte infiltration at the infarct in response to ischemic myocardial injury. Therefore, decreasing the activities of these monocytes immediately after acute myocardial infarction (AMI) could be beneficial for AMI patients. Objectives: This study tested the hypothesis that therapeutic siRNA-loaded photoluminescent mesoporous silicon nanoparticles (PMSNs) targeting CCR2 expression in Ly6C(high) inflammatory monocytes decrease the accumulation of these cells in the infarct, improve the efficacy of MSC transplantation and attenuate myocardial remodeling.Methods: PMSNs carrying therapeutic siCCR2 were first synthesized without the inclusion of fluorescent materials or dyes. After AMI BALB/c mice were established, 10(5) 5-ethynyl-2'- deoxyuridine (EdU)-labeled MSCs suspended in 100 mu l of phosphate buffered saline (PBS) were injected into the border zone of the infarct of each mouse. PMSNs-siCCR2 (25 mu g/g) were also intravenously injected via the tail vein immediately following AMI induction. Control mice were injected with an equal amount of PMSNs without siCCR2. PMSNs-siCCR2 were examined in vivo using near-infrared imaging technology. The therapeutic effects of PMSNs-siCCR2 for MSC transplantation were determined at the mRNA, protein and functional levels.Results: PMSNs-siCCR2 circulated freely in vivo and were cleared in a relatively short period of time (t(1/2) = 37 min) with no evidence of toxicity. The therapeutic PMSNs-siCCR2 showed higher levels of cellular accumulation in Ly6C(high) monocytes in the spleen and more efficient degradation of CCR2 compared with the control (8.04%+/- 2.17% vs. 20.02%+/- 4.55%, p<0.001). Subsequently, the PMSNs-siCCR2 decreased the accumulation of CD11b-positive monocytes at the infarct (49.3%+/- 17.34% vs. 61.32%+/- 22.43%, p<0.001) on day 1. Increased survival of transplanted MSCs (13 +/- 3/mm(2) vs. 4 +/- 1/mm(2), p<0.001) and significantly decreased TdT-mediated dUTP nick end labeling (TUNEL)(+) cardiac myocytes (17.44%+/- 6.26% vs. 39.49%+/- 13.28%, p<0.001) were then identified in the infarct zone three days after AMI induction in the PMSNs-siCCR2 group. Three weeks after MSC injection, significant increases were observed in the vascular density (235.5 +/- 39.6/mm(2) vs. 147.4 +/- 20.3/mm(2), p<0.001) and the cardiac myosin-positive area (21.7%+/- 8.4% vs. 13.2%+/- 4.4%, p<0.001) of the infarct border zone. In addition, significant amelioration of left ventricular (LV) remodeling (thickness of the LV posterior walls) (0.84 +/- 0.11 mm vs. 0.61 +/- 0.08 mm, p<0.001) was also observed at the same time compared with the control group.Conclusions: PMSNs-siCCR2-mediated CCR2 gene silencing in Ly6C(high) monocytes improved the effectiveness of MSC transplantation and selectively ameliorated myocardial remodeling after AMI. These results suggest that PMSNs-siCCR2 could potentially be used to develop an anti-inflammatory therapy for post-AMI MSC transplantation.

Enhancing Cardiac Repair by Allogeneic MSC via Downregulation of B2M by CRISPR/Cas9 Technology

Downregulation Of B2m In Allogeneic Msc By Crispr Technology Inhibits Immune Rejection And Enhances Cardiac Repair

Inhibiting Immune Rejection And Enhancing Ischemic Hindlimb Repair By B2m Knockdown In Allogeneic Human Msc Using Crispr/Cas9 Technology

Knockout of beta-2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell-induced immune rejection

C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.

Mineralocorticoid Receptor Deficiency Improves The Therapeutic Effects Of Mesenchymal Stem Cells For Myocardial Infarction Via Enhanced Cell Survival

Transplantation of CRISPRa System Engineered IL10-overexpressing Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Myocardial Infarction in Diabetic Mice

Knockout of Beta-2 Microglobulin Reduces Stem Cell-Induced Immune Rejection and Enhances Ischemic Hindlimb Repair Via Exosome/mir-24/Bim Pathway in Mice

Mesenchymal stem cells with overexpression of midkine enhance cell survival and attenuate cardiac dysfunction in a rat model of myocardial infarction

Combined Intrathymic and Intravenous Injection of Mesenchymal Stem Cells Can Prolong the Survival of Rat Cardiac Allograft Associated with Decrease in Mir-155 Expression

Knockout of beta‐2 microglobulin reduces stem cell‐induced immune rejection and enhances ischaemic hindlimb repair via exosome/miR‐24/Bim pathway

Abstract 17615: MSC Exosome Mediated Myocardial Repair is Inhibited by Knockdown of Igf-1 Signaling Pathway Through CRISPR/Cas9 Genome Editing

Targeted Migration of Mesenchymal Stem Cells Modified with CXCR4 Gene to Infarcted Myocardium Improves Cardiac Performance

Photoluminescent Mesoporous Silicon Nanoparticles With Siccr2 Improve The Effects Of Mesenchymal Stromal Cell Transplantation After Acute Myocardial Infarction

Pretreatment of Cardiac Stem Cells With Exosomes Derived From Mesenchymal Stem Cells Enhances Myocardial Repair.

Transplantation of Mesenchymal Stem Cells from Human Bone Marrow Improves Damaged Heart Function in Rats.

Enhancement of the survival of engrafted mesenchymal stem cells in the ischemic heart by TNFR gene transfection.

Abstract 15107: Comparative Therapeutic Efficacy and Mechanism of Stem Cells in Rat Myocardial Infarction Model

Mesenchymal Stem Cells with Enos Over-Expression Enhance Cardiac Repair in Rats with Myocardial Infarction

Nanotherapy‐Engineered Stem Cells Alleviate Myocardial Reperfusion Injury by Normalizing the Pathological Microenvironment and Promoting Cardiac Repair

Purified Human Bone Marrow Multipotent Mesenchymal Stem Cells Regenerate Infarcted Myocardium in Experimental Rats